PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Clinical trials for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT explained in plain language.
Never miss a new study
Get alerted when new PROSTATIC NEOPLASMS, CASTRATION-RESISTANT trials appear
Sign up with your email to follow new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new daily pill slow advanced prostate cancer?
Disease control Recruiting nowThis early-stage trial tests whether an experimental drug called FX-111 is safe enough to study further in men with metastatic castration-resistant prostate cancer (mCRPC), a form of advanced prostate cancer that no longer responds to standard hormone therapy. Participants take F…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1 • Sponsor: Flare Therapeutics Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for Hard-to-Treat prostate cancer: Immune-Targeting drug combo enters final testing
Disease control Recruiting nowThis Phase 3 trial tests whether adding pasritamig, a drug that directs the body's T-cells to attack prostate cancer cells, to standard chemotherapy (docetaxel) can slow cancer growth better than chemotherapy alone. The study involves 800 men with metastatic castration-resistant …
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Radiation plus hormone therapy may slow resistant prostate cancer
Disease control Recruiting nowThis study tests whether adding precise, high-dose radiation (SBRT) to standard second-generation antiandrogen drugs (enzalutamide or abiraterone) can better control prostate cancer that has spread to a few spots and stopped responding to hormone therapy. About 51 men with oligom…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE2 • Sponsor: Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for Hard-to-Treat prostate cancer: experimental drug combo trial opens
Disease control Recruiting nowThis clinical trial is testing an experimental drug called opevesostat (MK-5684), either alone or combined with other cancer drugs, in people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The study involves 220 participants and has t…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New 'See and Treat' approach targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests two copper-based drugs that work together: one helps doctors see prostate cancer tumors on scans, and the other delivers targeted radiation to kill them. The trial involves 54 men with a type of advanced prostate cancer that no longer responds to hormone therapy.…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug duo takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests two drugs—gedatolisib and darolutamide—together in men with metastatic castration-resistant prostate cancer (mCRPC), a type that has spread and no longer responds to standard hormone therapy. The first part finds the safest dose, and the second checks if the comb…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental combo aims to tackle Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called TVB-2640 combined with the standard drug enzalutamide (Xtandi) in 30 men whose prostate cancer has spread and stopped responding to hormone therapy. The main goal is to find the safest dose of TVB-2640 when used with enzalutamide and…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Massive data dive aims to uncover best prostate cancer treatments in real life
Knowledge-focused Recruiting nowThis study looks at how men with advanced prostate cancer that no longer responds to hormone therapy are treated in real-world clinics across the United States. Researchers will analyze data from over 17,000 patients to see which therapies are used, in what order, and how long th…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Mapping the next steps: how men with advanced prostate cancer are treated after standard therapies fail
Knowledge-focused Recruiting nowThis study looks at real-world data from over 1,000 men with metastatic castration-resistant prostate cancer (mCRPC) who have already received several standard treatments, including hormone therapy, chemotherapy, and a targeted radiation drug called Lu-177 PSMA-617. Researchers w…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC